Cancer
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
Top Ten most popular articles on Pharmafile.com this week
May 25, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Gielad, Novartis, brexit, obesity, pharma, top ten
It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …
Sun Pharma drug combo scores FDA approval in advanced castration-resistant prostate cancer
May 23, 2018Research and Development, Sales and Marketing Cancer, Churchill Pharmaceuticals, FDA, Sun Pharma, US, Yonsa, pharma, prostate cancer
Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in …
Top Ten most popular articles on Pharmafile.com this week
May 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, Novartis, Takeda, Trump, brexit, pharma, pharmafile, top ten
The year is flying by – it’s another Friday, and that means another Top Ten run-down.Perhaps the biggest story this …
New cancer clinical trial model promises to cut costs and development time
May 15, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, Cancer, MD AndersonCancer Center, clinical trials, pharma
Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the …
Lilly chalks up another acquisition with AurKa for $575m
May 14, 2018Manufacturing and Production, Sales and Marketing AurKa, Cancer, Eli Lilly, acquisition, oncology, pharma
Swiftly following up its $1.6 billion splash to pick up Armo BioSciences last week, Eli Lilly has agreed to acquire …
Medigene and bluebird bio expand immunotherapy partnership to $1.5bn
May 14, 2018Research and Development, Sales and Marketing Bluebird Bio, Cancer, Medigene, pharma
Medigene has announced that it has bolstered the existing partnership it has in place with US firm bluebird bio, originally …
Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer
May 11, 2018Medical Communications, Research and Development Cancer, Cotellic, Roche, pharma, tecentriq
Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …
NanoBots: The science of small to dwarf the disease
May 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Precision Medicine, nanorobots, pharma
Anjali Shukla delves into the exciting, miniature world of nanorobotics to explore how the ground-breaking technology promises to change the …
The new and improved Spring 2018 edition of Pharmafile is available to read online now!
May 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile
The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …
European approval for tablet formulation of Lynparza in ovarian cancer
May 8, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …
FDA approves Novartis combo in rare thyroid cancer subtype
May 8, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer
The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer
April 30, 2018Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …
UK media coverage vastly underrepresents older cancer patients and their risk, study finds
April 26, 2018Medical Communications, Research and Development Cancer, Cancer Research UK, UK, University of Glasgow, pharma
A Cancer Research UK-funded study undertaken by the University of Glasgow has revealed that representation and coverage of cancer patients …
Lilly’s arthritis drug found to prevent potentially lethal stem cell transplant complications
April 25, 2018Research and Development Cancer, Eli Lilly, JAK inhibitors, Stem cells, baricitinib, graft-versus-host disease, pharma
Researchers at St Louis Washington University School of Medicine have uncovered a promising extra application of a particular Janus Kinase …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
